Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To examine the trends and characteristics of opioid-related hospital admissions in England over 10 years, and its burden for the National Health Service and public finances.
Design: Patient-level data from the Hospital Episode Statistics database to examine all opioid-related hospitalisations from 2008 to 2018, stratified by type of opioid admission and patient demographics.
Setting: All National Health Service hospitals in England.
Participants: Patients hospitalised from the harmful use of opioids.
Main Outcome Measures: The number of opioid-related hospitalisations, length of stay, in-hospital mortality, 30-day readmission rate and treatment costs.
Results: Opioid-related hospitalisations increased by 48.9%, from 10,805 admissions in 2008 to 16,091 admissions in 2018, with total treatment costs of £137 million. The growth in opioid-related hospitalisations was 21% above the corresponding rate for all other emergency admissions in England. Relative changes showed that hospitalisations increased most for individuals older than 55 years (160%), those living in the most affluent areas of England (93.8%), and suffering from four co-morbidities (627.6%) or more. Hospitals reduced mean patient length of stay from 2.8 days to 1.1 days over 10 years. Mean in-hospital mortality was 0.4% and mean 30-day readmission risk was 16.6%.
Conclusion: Opioid use is an increasing public health concern in England, though hospitalisation and mortality rates are less pronounced than in other countries. There are concerns about significant rises in hospitalisations from older, less deprived and sicker population groups. Our findings should prompt policymakers to go beyond monitoring mortality statistics when assessing the impacts of harmful use of opioids.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066666 | PMC |
| http://dx.doi.org/10.1177/01410768221077360 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medications for Opioid Use Disorder in County Jails - Outcomes after Release.
N Engl J Med
September 2025
Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst.
Background: In 2019, seven county correctional facilities (jails) in Massachusetts initiated pilot programs to provide all Food and Drug Administration-approved medications for opioid use disorder (MOUD).
Methods: This observational study used linked state data to examine postrelease MOUD receipt, overdose, death, and reincarceration among persons with probable opioid use disorder (OUD) in carceral settings who did or did not receive MOUD from these programs from September 1, 2019, through December 31, 2020. Log-binomial and proportional-hazards models were adjusted for propensity-score weights and baseline covariates that remained imbalanced after propensity-score weighting.
Trends in prenatal opioid use disorder in California, 2010-2022.
Am J Prev Med
September 2025
Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, USA.
Introduction: Opioid-related deaths among perinatal populations have increased sharply in the United States. Whether the recent ascendence of illicit fentanyl and other synthetic opioids in the drug supply translates to increasing prenatal opioid use disorder (OUD) remains unknown. This study tested whether California's comparatively late fentanyl influx, in 2019, was associated with a subsequent increase in OUD among pregnant people.
View Article and Find Full Text PDFOpioid agonist therapy for opioid use disorder in primary versus specialty care.
Cochrane Database Syst Rev
September 2025
Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada.
Background: Opioid use disorder (OUD) is commonly treated in specialized care settings with long-acting opioid agonists, also known as opioid agonist therapy, or OAT. Despite the rise in opioid use globally and evidence for a 50% reduction in mortality when OAT is employed, the proportion of people with OUD receiving OAT remains small. One initiative to improve the access and uptake of OAT could be to offer OAT in a primary care setting; primary care clinics are more numerous, might reduce the visibility and potential stigma of receiving treatment for OUD, and may facilitate the care of other medical conditions that are unrelated to OUD.
View Article and Find Full Text PDFSafety and Efficacy of Dexmedetomidine in Spinal Fusion: A Systematic Review and Meta-Analysis Dexmedetomidine in Spinal Fusion Surgery.
J Pain Palliat Care Pharmacother
September 2025
Spine Unit, Orthopaedic Surgery and Traumatology Department, Catholic University and Polytechnic Hospital, Valencia, Spain.
Dexmedetomidine (DEX) has been proposed as an opioid-sparing adjunct after spinal fusion, but its efficacy across age groups is unclear. We conducted a systematic review and meta-analysis following PRISMA and registered in International Prospective Register of Systematic Reviews (PROSPERO) (CRD42024531252). Twelve studies (RCTs and cohorts; n=1,644) were included.
View Article and Find Full Text PDFRelationship Between State Policies Targeting Unethical Treatment Practices and Opioid-Related Outcomes: An Event Study Analysis.
Subst Use Addctn J
October 2025
Partnered Evidence-based Policy Resource Center, Boston VA Healthcare System, Boston, MA, USA.
Objectives: To estimate the effect of the passage of state laws targeting patient brokering on opioid-related outcomes.
Background: In response to growing awareness of unethical substance use disorder (SUD) treatment practices, several states in the United States have passed laws targeting patient brokering and deceptive marketing. Patient brokering and deceptive marketing laws are intended to reduce the chances individuals with SUD interact with bad actors or suffer from adverse outcomes related to inappropriate SUD treatment, but the effectiveness of these laws is unknown.